Surging Financial News
On the evening of September 15, Yunnan Watson Biotechnology Co., Ltd. (Watson Biology, 300142) released a message through the official WeChat public account that on the evening of September 14, Watson Biotechnology and Suzhou Aibo Biotechnology Co., Ltd. (hereinafter referred to as "Aibo Bio") jointly developed the mra new crown vaccine The first Mexican researcher meeting held an online meeting, which was the first overseas researcher kick-off meeting of the vaccine's global multi-center Phase III clinical trial.
Watson Bio said that this meeting is an important milestone for the domestic new crown MRA vaccine project to go to sea, and it is one step closer to the listing of the vaccine.
According to Watson Biology, the global multicenter phase III clinical trial of its MNA covid-19 vaccine will evaluate the protective efficacy, safety and immunogenicity of the vaccine in people aged 18 years and older. At the beginning of September, this batch of clinical samples has been exported to Mexico, and the samples will arrive at major clinical sites in the next week, and enrollment will soon start. Watson Bio will also send a clinical team to Mexico this week to assist in clinical work. (The Paper's reporter Li Xiaoxiao)
Editor-in-Charge: Xiaoxiao Li
![Explosive melon, the richest man quietly built a warehouse Watson creature, pay close attention to the melon of the possible more preemptive Watson creatures a brain hole[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)